Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia
Étienne Crickx, Sylvain Audia, A. Robbins, David Boutboul, Thibault Comont, Morgane Cheminant, Éric Oksenhendler, Bertrand Godeau, Marc Michel, Matthieu Mahévas
Abstract
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia Immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (AIHA) are antibody-mediated autoimmune diseases in which plasma cells secrete pathogenic antibodies directed against platelet and red blood cell antigens. 1 Some patients show no response to first-or second-line treatments, including corticosteroids, rituximab, immunosuppressive drugs, splenectomy and, in the case of ITP, thrombopoietin receptor agonists, a situation that increases the risk of morbidity and mortality. In these refractory cases, persistent autoreactive long-lived plasma cells in the bone marrow could explain treatment failure.